Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Novel allogeneic BCMA CAR-expressing iNKT cells with PD1 deletion demonstrate superior tumor control in a multiple myeloma preclinical model

View Full Paper
Ask AI
Bookmark
Share

Authors

SYShulin YangBZBiao ZhouYCYuzhu Cui

Discussion

Loading...

Member takes

Overview

Preclinical model reveals enhanced tumor control with PD1-deleted CAR-iNKT cells in multiple myeloma, suggesting benefits for cell therapy.

Key Points

  • The aim is to evaluate the efficacy of novel allogeneic PD1-deleted iNKT cell therapy targeting BCMA in multiple myeloma.
  • Developed a novel allogeneic PD1-deleted CAR-iNKT cell product targeting BCMA.
  • Compared therapeutic efficacy of modified and unmodified CAR-iNKT cells using a xenograft myeloma model.
  • Monitored disease burden using bioluminescence in NOG-hIL15Tg mice with H929-luc cells.
  • The CAR-iNKT cell with PD1 deletion showed increased long-term cytotoxicity against H929 cells in vitro.
  • In vivo, PD1-deleted CAR-iNKT demonstrated superior tumor control compared to unmodified CAR-iNKT cells.
  • Optimal dosing with three injections of CAR-iNKT with PD1 deletion showed significant tumor control until day 35.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d193https://doi.org/10.1182/blood-2025-5847
View Full Paper
Ask AI
Bookmark
Share